Actionable news
All posts from Actionable news
Actionable news in CLVS: Clovis Oncology, Inc.,

FDA staff casts doubt on Clovis' lung cancer drug

* Staff also recommend black box warning

* Drug still approvable - analysts

* Shares fall 5 pct in choppy trading (Adds analyst comment; updates shares)

April 8 (Reuters) - U.S. Food and Drug Administration staff members on Friday questioned whether Clovis Oncology Inc's lung cancer drug was superior to existing treatments and also raised concerns about its safety profile.

The drug, rociletinib, like rival Tagrisso from AstraZeneca Plc , aims to treat a sub-set of patients with advanced non-small cell lung cancer whose disease has worsened despite treatment.

"It's ugly, but we think the drug could still get approved, though timing is up in the air and its...